Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights.

Fandella A, Scattoni V, Galosi A, Pepe P, Fiorentino M, Gaudiano C, Giampaoli M, Gunelli R, Martino P, Montanaro V, Montironi R, Pierangeli T, Stabile A, Bertaccini A.

Anticancer Res. 2017 Feb;37(2):413-424. Review.

PMID:
28179286
2.

Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.

Pepe P, Garufi A, Priolo G, Pennisi M.

Clin Genitourin Cancer. 2017 Feb;15(1):e33-e36. doi: 10.1016/j.clgc.2016.07.007. Epub 2016 Jul 21.

PMID:
27530436
3.

Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B.

BJU Int. 2017 Nov;120(5):631-638. doi: 10.1111/bju.13711. Epub 2016 Dec 21.

4.

Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.

Kuru TH, Roethke MC, Seidenader J, Simpfendörfer T, Boxler S, Alammar K, Rieker P, Popeneciu VI, Roth W, Pahernik S, Schlemmer HP, Hohenfellner M, Hadaschik BA.

J Urol. 2013 Oct;190(4):1380-6. doi: 10.1016/j.juro.2013.04.043. Epub 2013 Apr 19.

PMID:
23608676
5.

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.

Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.

PMID:
28336078
6.

Magnetic resonance imaging in prostate cancer detection and management: a systematic review.

Monni F, Fontanella P, Grasso A, Wiklund P, Ou YC, Randazzo M, Rocco B, Montanari E, Bianchi G.

Minerva Urol Nefrol. 2017 Dec;69(6):567-578. doi: 10.23736/S0393-2249.17.02819-3. Epub 2017 May 8. Review.

7.

Magnetic Resonance and Ultrasound Image Fusion Supported Transperineal Prostate Biopsy Using the Ginsburg Protocol: Technique, Learning Points, and Biopsy Results.

Hansen N, Patruno G, Wadhwa K, Gaziev G, Miano R, Barrett T, Gnanapragasam V, Doble A, Warren A, Bratt O, Kastner C.

Eur Urol. 2016 Aug;70(2):332-40. doi: 10.1016/j.eururo.2016.02.064. Epub 2016 Mar 16.

PMID:
26995327
8.

Multiparametric MRI in detection and staging of prostate cancer.

Boesen L.

Dan Med J. 2017 Feb;64(2). pii: B5327. Review.

PMID:
28157066
9.

Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.

Radtke JP, Kuru TH, Bonekamp D, Freitag MT, Wolf MB, Alt CD, Hatiboglu G, Boxler S, Pahernik S, Roth W, Roethke MC, Schlemmer HP, Hohenfellner M, Hadaschik BA.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):283-91. doi: 10.1038/pcan.2016.16. Epub 2016 May 17.

PMID:
27184812
10.

Diagnostic Value of Cognitive-Registration Multiparametric Magnetic Resonance Guided Biopsy for the Detection of Prostate Cancer after Initial Negative Biopsy.

Tomašković I, Pezelj I, Bolanča Čulo K, Novosel L, Nikles S, Tomić M, Reljić A, Katušić J, Knežević M, Pirša M, Kruslin B, Ulamec M, Ružić B.

Acta Clin Croat. 2018 Oct;57(Suppl 1):40-45. doi: 10.20471/acc.2018.57.s1.05.

PMID:
30457246
11.

In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?

Salami SS, Ben-Levi E, Yaskiv O, Ryniker L, Turkbey B, Kavoussi LR, Villani R, Rastinehad AR.

BJU Int. 2015 Apr;115(4):562-70. doi: 10.1111/bju.12938.

12.

Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.

Pepe P, Cimino S, Garufi A, Priolo G, Russo GI, Giardina R, Reale G, Pennisi M, Morgia G.

Scand J Urol. 2017 Aug;51(4):260-263. doi: 10.1080/21681805.2017.1313310. Epub 2017 May 17.

PMID:
28513296
13.

The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.

Mowatt G, Scotland G, Boachie C, Cruickshank M, Ford JA, Fraser C, Kurban L, Lam TB, Padhani AR, Royle J, Scheenen TW, Tassie E.

Health Technol Assess. 2013 May;17(20):vii-xix, 1-281. doi: 10.3310/hta17200. Review.

14.

Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.

Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ.

Eur Urol. 2016 Jun;69(6):1129-34. doi: 10.1016/j.eururo.2015.11.018. Epub 2015 Dec 2.

PMID:
26651990
15.

The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Muller BG, Fütterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, Moul JW, Pinto PA, Rastinehad AR, Robertson C, de la Rosette J, Sanchez-Salas R, Jones JS, Ukimura O, Verma S, Wijkstra H, Marberger M.

BJU Int. 2014 Feb;113(2):218-27. doi: 10.1111/bju.12243. Epub 2013 Nov 13.

16.

Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.

Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.

BJU Int. 2017 Apr;119(4):535-542. doi: 10.1111/bju.13624. Epub 2016 Sep 3.

17.

Random biopsy: when, how many and where to take the cores?

Scattoni V, Maccagnano C, Capitanio U, Gallina A, Briganti A, Montorsi F.

World J Urol. 2014 Aug;32(4):859-69. doi: 10.1007/s00345-014-1335-0. Epub 2014 Jun 8. Review.

PMID:
24908067
18.

[Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].

Kesch C, Radtke JP, Distler F, Boxler S, Klein T, Hüttenbrink C, Hees K, Roth W, Roethke M, Schlemmer HP, Hohenfellner M, Hadaschik BA.

Urologe A. 2016 Aug;55(8):1071-7. doi: 10.1007/s00120-016-0093-6. German.

PMID:
27168038
19.

Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.

Volkin D, Turkbey B, Hoang AN, Rais-Bahrami S, Yerram N, Walton-Diaz A, Nix JW, Wood BJ, Choyke PL, Pinto PA.

BJU Int. 2014 Dec;114(6b):E43-E49. doi: 10.1111/bju.12670. Epub 2014 Oct 18.

20.

Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate.

Kuru TH, Roethke MC, Rieker P, Roth W, Fenchel M, Hohenfellner M, Schlemmer HP, Hadaschik BA.

BJU Int. 2013 Dec;112(8):1080-7. doi: 10.1111/bju.12259. Epub 2013 Aug 13.

Supplemental Content

Support Center